Company: ACBM
Filing Date: 2025-07-18
Form Type: 10-K
Source: 0001640334-25-001245
Chunk: 374

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-18
Form: 10-K
Item: Item 4
Chunk 374
---
of Cash Flows

   Year Ended     December 31,    2023  2022        CASH FLOWS FROM OPERATING ACTIVITIES      Net loss $(8,807,573) $(15,871,443)Adjustments to reconcile net loss to net cash used in operating activities:        Imputed interest - related parties  3,206   1,706 Amortization of deferred stock compensation   8,060,983   15,712,400 Provision for doubtful accounts  480,000   - Provision for purchase deposit write-off  12,000   - Changes in operating assets and liabilities:        Accounts receivable  158,500   (40,500)Security deposit  (370)  - Prepaid expenses  (65)  (18)Accounts payable and accrued expenses  77,873   50,374 Net cash used in operating activities  (15,446)  (147,481)         CASH FLOWS FROM FINANCING ACTIVITIES        Advances from related parties  9,970   58,085 Net cash provided by financing activities  9,970   58,085          Net change in cash  (5,476)  (89,396)Cash at beginning of year  5,852   95,248 Cash at end of year $376  $5,852          SUPPLEMENTAL CASH FLOW INFORMATION:        Cash paid for income taxes $-  $- Cash paid for interest $-  $-          NON CASH INVESTING AND FINANCING ACTIVITIES        Increase in the right-of-use asset and lease liability $52,233  $- 

The accompanying notes are an integral part of these financial statements.

 F-7Table of Contents

ACRO BIOMEDICAL CO., LTD.

Notes to the Financial Statements

NOTE 1 -ORGANIZATION AND DESCRIPTION OF BUSINESS Acro Biomedical Co., Ltd. (the “Company”) is a Nevada corporation incorporated on September 24, 2014 under the name Killer Waves Hawaii, Inc. On January 30, 2017, the Company’s corporate name was changed to Acro Biomedical Co., Ltd